Skip to main content

A Phase II Study of NirAparib, Dostarlimab and Radiotherapy in Metastatic, PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR) TBCRC-055 20-649

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

GlaxoSmithKline

Start Date

November 16, 2023

End Date

March 31, 2028
 

Administered By

Duke Cancer Institute

Awarded By

GlaxoSmithKline

Start Date

November 16, 2023

End Date

March 31, 2028